Predict your next investment

hemotune company logo
HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
hemotune.ch

See what CB Insights has to offer

Executives

2

Board of Directors

1

hemotune Board of Director

1 Board of directors

hemotune has 1 board of directors, including Didier Cowling.

Name

Firm

Work History

Other Seats

Didier Cowling

Didier Cowling joined hemotune as President of the Board of Directors in 2019. He started his career as an investment analyst, first at Nomura and then at HSBC, forming a highly rated pharma and medtech team. He then moved into industry to be Director of Business Development at Phairson Medical Ltd. In 2000, he co-founded Kuros Therapeutics AG, which was successfully sold in 2002. Subsequently, he co-founded Kuros Biosurgery AG, which worked on developing a number of drug/device combination products. In early 2016, Kuros Biosurgery merged with Cytos Biotechnology and was renamed Kuros Biosciences AG, becoming public on the Swiss Exchange. Didier retired as President & CEO of the Kuros group in 2018 and is now working with a number of SMEs in the life science space, helping them to form and grow, both as an advisor and at Board level. As a serial entrepreneur and board member with over 30 years of broad experience in the field, Didier brings to hemotune his deep knowledge of the medtech industry and hands-on start-up experience.

hemotune, and hemotune

Name

Didier Cowling

Firm

Work History

Didier Cowling joined hemotune as President of the Board of Directors in 2019. He started his career as an investment analyst, first at Nomura and then at HSBC, forming a highly rated pharma and medtech team. He then moved into industry to be Director of Business Development at Phairson Medical Ltd. In 2000, he co-founded Kuros Therapeutics AG, which was successfully sold in 2002. Subsequently, he co-founded Kuros Biosurgery AG, which worked on developing a number of drug/device combination products. In early 2016, Kuros Biosurgery merged with Cytos Biotechnology and was renamed Kuros Biosciences AG, becoming public on the Swiss Exchange. Didier retired as President & CEO of the Kuros group in 2018 and is now working with a number of SMEs in the life science space, helping them to form and grow, both as an advisor and at Board level. As a serial entrepreneur and board member with over 30 years of broad experience in the field, Didier brings to hemotune his deep knowledge of the medtech industry and hands-on start-up experience.

Other Seats

hemotune, and hemotune

hemotune Management Team

2 Team Members

hemotune has 2 executives. hemotune's founder is Carlos Andrea Mora. hemotune's current Founder, Chief Executive Officer is Lukas Langenegger.

Name

Work History

Title

Status

Lukas Langenegger

Founder, Chief Executive Officer

Current

Carlos Andrea Mora

Founder

Current

Name

Lukas Langenegger

Carlos Andrea Mora

Work History

Title

Founder, Chief Executive Officer

Founder

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.